SCHEMBL6640261

SCHEMBL6640261

N#Cc1ccc2[nH]cc(C3CCC4(CC3)OCCO4)c2c1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 16/20 0.58
SLC6A2 P23975 2/20 0.55
SLC6A3 Q01959 2/20 0.55
HTR1A P08908 1/20 0.55
DRD1 P21728 1/20 0.55
HTR1B P28222 1/20 0.55
HTR2A P28223 1/20 0.55
HTR6 P50406 1/20 0.55
IDO1 P14902 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6636989 0.81 SLC6A4 (0.52) SLC6A4HTR1AHTR1BHTR6IDO1
SCHEMBL6636225 0.81 SLC6A4 (0.52) SLC6A4SLC6A2SLC6A3HTR1ADRD1
SCHEMBL6637981 0.81 SLC6A4 (0.52) SLC6A4HTR1AHTR1BHTR2AIDO1
SCHEMBL22439633 0.80 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3HTR1ADRD1
SCHEMBL2270899 0.80 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3HTR1ADRD1
SCHEMBL4674563 0.78 SLC6A4 (0.64) SLC6A4SLC6A2SLC6A3HTR1ADRD1
SCHEMBL6636344 0.78 MTNR1A (0.54) SLC6A4HTR1AHTR2AHTR6IDO1
SCHEMBL6635816 0.78 HTR2C (0.59) HTR2A
SCHEMBL5792377 0.77 SLC6A4 (0.63) SLC6A4SLC6A2SLC6A3HTR1ADRD1
SCHEMBL7484043 0.76 SLC6A4 (0.65) SLC6A4SLC6A2SLC6A3HTR1ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147083-B1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION WYETH CORP (US) 2004-06-16 EP disclosed
US-6465482-B2 ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; SEROTONIN-AFFECTED NERVOUS SYSTEM DISORDERS; ACTING AT THE 5-HT1A AUTORECEPTORS CONCOMMITANTLY WITH 5-HT TRANSPORTERS; ANTISEROTONIN AGENTS; SEROTONIN REUPTAKE INHIBITORS; HT3 RECEPTOR ANTAGONISTS WYETH 2002-10-15 US disclosed
US-20020045628-A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-18 US disclosed
US-6313126-B1 FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY AMERICAN HOME PRODUCTS CORP 2001-11-06 US disclosed
EP-1147083-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2001-10-24 EP disclosed
WO-2000040554-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045628-A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression HTR2C, TPH1, TPH2 SLC6A4 43/4885SLC6A2 155/4885SLC6A3 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.